Details

Autor(en) / Beteiligte

• Sen, Hanim
• Lam, Ming Kai
• Tandjung, Kenneth
• Löwik, Marije M.
• Stoel, Martin G.
• de Man, Frits H.A.F.
• Louwerenburg, J. (Hans) W.
• van Houwelingen, Gert K.
• Linssen, Gerard C.M.
• Doggen, Carine J.M.
• Basalus, Mounir W.Z.
• von Birgelen, Clemens

Titel

Complex patients treated with zotarolimus-eluting resolute and everolimus-eluting xience V stents in the randomized TWENTE trial: Comparison of 2-year clinical outcome

Ist Teil von

• Catheterization and cardiovascular interventions, 2015-01, Vol.85 (1), p.74-81

Ort / Verlag

United States: Blackwell Publishing Ltd

Erscheinungsjahr

2015

Quelle

Wiley Online Library Journals Frontfile Complete

Beschreibungen/Notizen

• Objective To assess the differences in clinical outcome between complex patients treated with Resolute zotarolimus‐eluting stents (ZES) versus Xience V everolimus‐eluting stents (EES). Background Nowadays, many complex patients with coronary disease are treated with percutaneous coronary interventions, using drug‐eluting stents (DES). Methods We analyzed 2‐year outcome data of 1,033 complex patients of the TWENTE trial, treated with second‐generation Resolute ZES or Xience V EES. Complex patients had at least one of the following characteristics: renal insufficiency (creatinine ≥ 140 µmol/l); ejection fraction < 30%; acute myocardial infarction (MI) within previous 72 hrs; >1 lesion/vessel; >2 vessels treated; lesion length > 27 mm; bifurcation; saphenous vein graft lesion; arterial bypass graft lesion; in‐stent restenosis; unprotected left main lesion; lesion with thrombus; or lesion with total occlusion. Target vessel failure (TVF), the primary composite endpoint of the trial, was defined as cardiac death, target vessel‐related MI, or target vessel revascularization. Results Among the 1,033 complex patients, 529 (51%) were treated with Resolute ZES and 504 (49%) with Xience V EES. Patient‐ and procedure‐related characteristics were similar between DES groups. After 2‐year follow‐up, outcome was also similar between DES groups. TVF occurred in 12.1% of patients treated with Resolute ZES and 12.3% of patients treated with Xience V EES. In addition, DES groups did not differ significantly in cardiac death, MI, or target vessel revascularization—the individual components of TVF. Conclusion Complex patients treated with Resolute ZES and Xience V EES showed similar safety and efficacy during 2‐year follow‐up. © 2014 Wiley Periodicals, Inc.